USPTO Awards Another Patent; New Data Demonstrating 14-3-3η as a Biomarker for Monitoring Therapy Response
USPTO Awards Patent for Citrullinated 14-3-3: Expanding Augurex’s Portfolio in the Diagnosis of Rheumatoid Arthritis (RA)
On November 20th, 2018 the US Patent and Trademark Office (USPTO) awarded patent number 10,132,806 entitled “Antigens Derived From Citrullinated 14-3-3 And Uses Thereof In The Diagnosis of Rheumatoid Arthritis.” Citrullinated 14-3-3η auto-antibodies are expressed in early and established RA and complement ACPA as a diagnostic aid. It’s hypothesized that patients with elevated levels of circulating citrullinated 14-3-3η may have a more favorable prognosis. 14-3-3η continues to pave the way for a future with better patient outcomes.
New published data demonstrating 14-3-3η as a biomarker for monitoring Tofacitinib therapy response in RA patients
14-3-3η is a modifiable marker of joint damage progression risk, which makes it ideal to track over time for the optimization of RA treat-to-target strategies to improve clinical and radiographic outcomes. The newly published study demonstrates how changes in 14-3-3η levels correlate with clinical disease activity measures in RA patients treated with Tofacitinib. It is expected that 14-3-3η will have an increasingly important role in the management of RA patients and this study highlighted 14-3-3η as a biomarker for monitoring therapy response. Read more
Comments are closed.